News

ADXS-HPV is Advaxis’s investigational Lm-LLO immunotherapy designed to treat human papillomavirus (HPV)-associated cancers, while epacadostat is Incyte’s investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor. As part of the

The collaboration will support the development, expansion and commercialization of Voyager’s new CNS product pipeline. It will also include several gene therapy programs for Parkinson’s disease (PD), Friedreich’s

By using the company’s Biochronomer polymer-based drug delivery platform, HTX-011 releases the local anesthetic bupivacaine and the anti-inflammatory meloxicam over an extended period. The Phase I trial in

The submission is for treatment of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r), dosed once daily in patients with genotype 1 (GT1) HCV infection. The application is based on data from the Phase

Since 2012, GSK owned a minority stake in Glycovaxyn, which has developed a biological conjugation platform technology that could help in the development of new prophylactic and therapeutic

The company said that TZ101 could potentially transform hematopoietic stem cell transplantation by reducing patient morbidity and mortality from GVHD. GVHD is a serious, life-threating complication of stem

Under the deal, Accelovance will support Panacea’s clinical development strategies by providing scientific/medical and regulatory expertise. Additionally, Accelovance will also provide contract research organization (CRO) support through project

The exclusive license was received through an amendment to Lion’s previously granted, non-exclusive, worldwide license to certain NIH issued and pending patent applications for the use of TIL

The U.S. Centers for Disease Control and Prevention (CDC) has identified C. difficile as an "urgent public health threat" that often occurs in people who have had recent